213 related articles for article (PubMed ID: 38184614)
21. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
[TBL] [Abstract][Full Text] [Related]
22. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
[TBL] [Abstract][Full Text] [Related]
23. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
24. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
[No Abstract] [Full Text] [Related]
25. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
[TBL] [Abstract][Full Text] [Related]
26. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract][Full Text] [Related]
27. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
28. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
29. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
30. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD).
Incorvaia L; Badalamenti G; Novo G; Gori S; Cortesi L; Brando C; Cinieri S; Curigliano G; Ricciardi GR; Toss A; Chiari R; Berardi R; Ballatore Z; Bono M; Bazan Russo TD; Gristina V; Galvano A; Damerino G; Blasi L; Bazan V; Russo A
ESMO Open; 2024 Jan; 9(1):102196. PubMed ID: 38118367
[TBL] [Abstract][Full Text] [Related]
32. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
[TBL] [Abstract][Full Text] [Related]
33. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
34. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
35. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
36. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
37. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
38. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
39. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
Shao C; Chang MS; Lam FC; Marley AR; Tang H; Song Y; Miller C; Brown M; Wan I; Han J; Adeboyeje G
J Oncol; 2022; 2022():5830475. PubMed ID: 35909902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
